Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer.

ABSTRACT: The chemotherapy backbone for patients with high-grade advanced epithelial ovarian cancer (HG-AOC) is carboplatin and paclitaxel followed by a maintenance therapy either with bevacizumab, with a PARP inhibitor, or with a combination of both, which is defined by the presence of a homologous recombination deficiency (HRD) and by the BRCA1/2 status. This study included patients with a primary diagnosis of HG-AOC treated between December 2019 and December 2021. The HRD status was measured using the Myriad myChoice^® test on all the patients with an indication for tumor HRD testing. Germline testing was conducted on all the patients using the TruRisk^® panel as recommended by the national guidelines. HRD testing was requested for 190 patients, and, for 163 patients (8

SUBMITTER: Heitz F 

PROVIDER: S-EPMC9913091 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature